The News Releases listed below describe just a few of the exciting things happening at MPI Research. Click on each one to read the full story.

• MPI Research Proactive in Response to Recent FDA Assessment of Abuse Potential of Drugs
  On January 26, 2010, the Food and Drug Administration (FDA) released a key draft guidance document, Guidance for Industry Assessment of Abuse Potential of Drugs. When finalized, this guidance will represent the FDA’s current position on the abuse potential of drugs. Noteworthy within the document, Good Laboratory Practices (GLP) specified in the Guidance for Industry S7A Safety 471 Pharmacology Studies for Human Pharmaceuticals and in FDA regulations, 21 CFR 472 part 58, now also apply to abuse potential studies in animals.
  
  
• Lean Six Sigma Initiative at MPI Research
  MPI Research is taking a proactive approach to the changes being faced by the pharmaceutical, biotech, and medical device industries it serves by adopting Lean Six Sigma (LSS) practices as an integral part of their quality initiative. Emerging challenges resulting from a combination of factors - the recent economic downturn, expirations of blockbuster drug patents, a dwindling pipeline, uncertainty about the future of healthcare reimbursement, and more merger and acquisition activity than ever before - have driven these industries to reassess competitive strategy. Via its LSS programs, MPI Research is assisting their pharma, biotech, and medical device customers in optimizing productivity, efficiency, and quality.
  
  
• Medicilon/MPI Preclinical Research-Shanghai Receives AAALAC Certification
  Medicilon/MPI Preclinical Research-Shanghai has been recognized as an accredited International Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC) facility. This accreditation further underscores the company's commitment to quality research. The AAALAC initiative was led by Lijie Fu, PhD, Executive Vice President of Operations, a national returnee with substantial industry, scientific and CRO experience.
  
  
• Strategic Collaboration with Kineta
  MPI Research announced that it will be collaborating with Kineta, Inc, a Seattle-based biotechnology company, in advancing their promising autoimmune drug development program. This collaboration will enable phase one human trials to begin in 2010. Recently named one of the nation's top ten most promising biotechnology companies by Pharmaceutical Executive (August 2009), more information about Kineta is available at www.Kinetabio.com.
  
  
• MPI Research Toxicologist Serves in Multiple Thoughtleader Roles
  Ali S. Faqi, DVM, PhD, DABT, Director of Developmental and Reproductive Toxicology (DART) and Senior Principal Study Director at MPI Research, has accepted an appointment to serve on the Board of Scientific Counselors Computational Toxicology Subcommittee (BOSC), a Federal Advisory Committee under the jurisdiction of the US Environmental Protection Agency. Dr. Faqi, who has published extensively and held many leadership roles in professional organizations, will serve as a BOSC member for one year. He will provide expert judgment on such topics as the quality and type of proposed research programs, excellence in research management practices, and the use of peer review in promoting sound science.
  
  
• Change in Director of Research at MPI Research
  Jim Laveglia, PhD, has passed the baton of Director of Research at MPI Research to Tina Rogers, PhD, MBA, DABT, formerly the company's Discovery Center Director. In his new role as Executive Vice President, Dr. Laveglia will focus on business development and will continue to serve on the company's Corporate Management Team and Board of Directors.
  
  
• MPI Research Announces Discovery Center Updates
  The MPI Research Discovery Center, operational since September 1, 2008, is moving forward with plans to transfer its services to new quarters. Located about 12 miles from corporate headquarters in Mattawan, the Discovery Center facilities will be located in downtown Kalamazoo, MI. The new accommodations will house customized state-of-the-art laboratories for all the discovery service offerings of the company, including Experimental Therapeutics (in vivo, molecular and cell-based assays), Experimental Surgery, Molecular Imaging, Drug Metabolism, Pharmacokinetics, and Immunology. Migration of these services to the new facilities will be completed over the next six to twelve months.
  
  
• MPI Research Announces its 4th Annual Educational Summit: Novel Therapeutic Biologics: Innovative Molecules and Mechanisms
  Register for the opportunity to learn alternative perspectives, network and to gain new insights in the development of novel protein therapeutic biologics. This event is brought to you by MPI Research, in collaboration with MichBio and the Van Andel Institute.
  
  
• MPI Research Honors the 30^th Anniversary of GLPs
  Please join MPI Research in recognizing June 2009 as marking the 30-year anniversary for GLP (Good Laboratory Practices) regulations within the preclinical research industry. Establishing in the 1970s by the US FDA in the Code of Federal Regulations (21 CFR Part 58), GLP Regulations were created to assure the quality, integrity, and reproducibility of the research data used to support preclinical laboratory studies. They became fully effective on June 20, 1979.
  
  
• Juvenile Toxicity Preclinical Testing Webinar
  Join Dr. Faqi for a stimulating discussion on key aspects of designing and implementing studies that support the use of drugs in the pediatric population. Historically, this data was often derived from the safety data generated from preclinical studies in adult animals and clinical studies in human adults. However, because of the differences in drug safety profiles between immature and mature organ systems, juvenile animal studies should be considered when identified target organ toxicity in adults is also an organ with significant postnatal development.
  
  
• MPI Research Announces Indian Office
  MPI Research announced on June 8, 2009 that in addition to its liaison offices currently established in strategic locations worldwide, it now has an office in India. Until now, the company has served the Indian biopharmaceutical market through its US-based headquarters in Mattawan, MI. However, because of the mounting research needs of India's growing biotechnology and pharmaceutical industries, MPI Research is opening an office in Ahmedabad, India.
  
  
• 100th annual meeting of the American Association for Cancer Research
  At the 100th annual meeting of the American Association for Cancer Research (AACR) being held April 18-22 in Denver, Zheng "Jim"Wang, PhD, Director of Molecular Imaging and Senior Study Director at MPI Research, will present a poster on the use of a new imaging agent for earlier tumor detection.
  
  
• Medicilon/MPI Preclinical Research-Shanghai Announces Dean Rodwell as President and Chief Operating Officer
  On March 2, 2009, Dean Rodwell joined the joint venture between MPI Research, Mattawan, Michigan, and Shanghai Medicilon, Shanghai, China, as President and Chief Operating Officer.  Reporting to the Board of Directors, Rodwell will oversee all of the day to day operations at the company.
  
  
• MPI Research Expansion in Kalamazoo
  MPI Research is pleased to announce its intent to take over two laboratory buildings in downtown Kalamazoo. Pfizer vacated the buildings, and MPI Research will renovate them to accommodate its growing discovery services. Read more details at MPI Research Expands into Kalamazoo Pfizer Buildings.
  
  
• Medicilon/MPI Preclinical Research Shanghai Introduces Board of Directors
  Mattawan, MI (April 2008) - Medicilon/MPI Preclinical Research Shanghai has announced its newly formed Board of Directors, which has equal representation from the two parent companies. The four directors include executives William U. Parfet and William Harrison from MPI Research, and Drs. Chun-Lin Chen and Jintao Zhang from Medicilon.
  
  
• MPI Research Announces Key Positions
  Mattawan, MI (February 2008) - MPI Research recently announced two key appointments. Zheng Jim Wang, PhD, is the Director of Molecular Imaging and Stefano F. Liparoto, PhD, is the Director of Immunology, and will head the company’s Immunoassay and Immunotoxicology area. As experts in their fields, the addition of Dr. Wang and Dr. Liparoto will expand the capabilities of MPI Research in these areas that are increasingly important to the drug discovery development programs of its Sponsors.
  
  
• MPI Research and Shanghai Medicilon Announce Shanghai-Based Joint Venture
  MPI Research and Shanghai Medicilon are pleased to announce a new joint venture to form Medicilon-MPI Preclinical Research (Shanghai) LLC. Located initially at the Zhangjiang Hi-Tech Park in Shanghai, China, the company will open a 50,000ft2 preclinical testing facility in the Chuansha Economic Park in early 2008. This new facility will meet the regulatory standards set forth by the US FDA and other regulatory agencies worldwide.
  
  
• MPI Research at AusBiotech 2007 National Conference October 21-24 in Brisbane
  MPI Research, a global provider of preclinical drug discovery and development services for the pharmaceutical and biotechnology industries, will have an active role at the AusBiotech 2007 National Conference being held at the Brisbane Convention and Exhibition Center in Brisbane, Queensland, Australia from October 21 through October 24. The company will present a half-day educational seminar, Aiming for Preclinical Success, on October 21 from 1:30 pm to 5:30 pm on the mezzanine level of the convention center.
  
  
• MPI Research Fills Key Leadership Positions
  Two high level appointments within MPI Research were recently announced. David Serota, PhD, DABT, was promoted to the position of Vice President, Toxicology and Pathology and will also serve as a member of the company’s senior management team. Tina Rogers, PhD, DABT, joined the company as the Associate Director of Research. Both appointments further strengthen the leadership position MPI Research has earned within the Contract Research Organization (CRO) industry.
  
  
• MPI Research Continues Toxicology Expansion
  Additional capacity keeps the pharmaceutical industry's preclinical drug development programs moving forward - As part of a series of planned expansions, MPI Research announced the immediate availability of additional toxicology capacity today. Through its portfolio of services the company generates critical safety data for the pharmaceutical and biotechnology industries prior to a new drug candidate's introduction to humans.
  
  
• MPI Research Presents Annual Education Summit - Advances in Therapeutic Discovery & Drug Development: Preclinical Cell-Based Therapy Research - MPI Research, a preclinical contract research organization that sponsors annual educational summits, is proud to present, Advances in Therapeutic Discovery and Drug Development: Preclinical Cell-Based Therapy Research, August 15-17, 2007 at the historic and picturesque Brook Lodge in Augusta, Michigan.
  
  
• MPI Research at Japanese Society of Toxicology June 27-29 in Tokyo - As a global leader in preclinical research for the pharmaceutical and biotech industries, MPI Research will be active at the esteemed Japanese Society of Toxicology (JST) meeting being held at the Tower Hall Funabori in Tokyo, Japan on June 27-29, 2007.
  
  
• MPI Research Teams with NYBA
  MPI Research presents and exhibits at the 16th Annual Meeting of the New York Biotechnology Association (NYBA) on April 10, 2007 - MPI Research is pleased to be an integral part of the 16th NYBA annual meeting, being held on April 10, 2007 at the Marriott Marquis Hotel in New York City. Stephen Frantz, PhD, DABT, MPI Research Director of Pharmaceutical Development and Senior Principal Study Director, will be one of three panelists discussing “FDA Requirements for New Drug Development – Enabling Your IND.”
  
  
• MPI Research Expands Toxicology Capacity
  New facilities provide timely study starts to meet the pharmaceutical industry's growing research and development needs - MPI Research announced the availability of additional toxicology capacity today. Through its portfolio of services the company generates critical safety data for the pharmaceutical and biotechnology industries prior to a new drug candidate's introduction to humans.
  
  
• MPI Research exhibits (booths 985 and 1546) and educates at the AAPS Annual Meeting and Exposition, October 29-November2, 2006 - With its recent acquisition of Exygen Research, MPI Research, a leader worldwide in preclinical drug discovery and development research, will have an expanded presence at the Annual Meeting and Exposition of the American Association of Pharmaceutical Scientists. Being held October 29 – November 2, 2006 in San Antonio, Texas, meeting attendees can visit MPI Research in booths 985 and booth 1546. Booth 985 will focus on the entire scope of services that are available at MPI Research, which supports research programs from drug discovery through regulatory submission. At booth 1546, our newly enhanced range of analytical services, which includes 160 talented professionals dedicated solely to analytical research, 60,000 ft2 of analytical laboratory space, and 38 LC-MS/MS systems, will be featured.
  
  
• MPI Research Acquires Exygen Research -MPI Research is pleased to announce its acquisition of Exygen Research, a Pennsylvania firm that provides high quality analytical services to the pharma, biotech, and chemical industries. Exygen Research will continue to operate from its State College PA location and will assume the management of all analytical services, including those offered at the Mattawan site. In addition to substantially enlarging the analytical scientific team, laboratory space is also significantly expanded with this acquisition. Sponsors will have access to a broader range of analytical equipment, instrumentation, and software. Customers currently doing business with Exygen will now have access to a greater scope of preclinical drug discovery and development research services.
  
  
• 2006-09-12 - MPI Research presents and exhibits (booth 4) at the 6th Annual Meeting of the Safety Pharmacology Society, September 26-28, 2006 in San Diego, California - MPI Research, a leader worldwide in preclinical drug discovery and development research, is honored to play an active role in the 6th annual meeting of the Safety Pharmacology Society, being held September 26-28, 2006 at the Town and Country Resort and Convention Center in San Diego, California. We are pleased to announce a timely program of poster presentations, detailing the recent efforts of MPI Research scientists on our Safety Pharmacology team...
  
  
• 2006-07-31 - Join MPI Research in Booth 323 at the 11th Annual World Congress on Drug Discovery Technology & Development, August 8-10 in Boston, MA. - As an industry leader in targeted discovery research, MPI Research is proud to be a part of the 11th Annual World Congress on Drug Discovery Technology and Development. Visit us at BOOTH 323 to learn how the range of models developed by our diverse and experienced drug discovery research team have expedited the discovery and development processes for many of our pharmaceutical, biotech, medical device, and animal health Sponsors. With experience in conducting studies with human as well as rat stem cells, our Sponsors also benefit from the in vitro support available in our tissue culture facility, BSL-2 laboratory for pathogen handling, and our flow cytometry laboratory..
  
  
• 2006-07-12 - MPI Research providing GLP training at the China Life Sciences Summit, July 27th & 28th in Beijing - As a global leader in preclinical pharmaceutical, biopharmaceutical and medical device research and development, MPI Research will conduct training on Good Laboratory Practices (GLP) compliance at the esteemed China Life Sciences Summit, being held in Beijing, PRC on July 27-28, 2006.
  
  
• 2006-05-24 - Presenting Advances in Therapeutic Discovery & Drug Development: Molecular Imaging in Translational Research - Don't miss out on the exciting developments that are occurring with non-invasive molecular imaging in pharmaceutical research at the upcoming summit, Advances in Therapeutic Discovery and Drug Development: Molecular Imaging in Translational Research. Sponsored by MPI Research, in collaboration with the Society of Non-Invasive Imaging in Drug Development and the Academy of Molecular Imaging, this summit will be held in the heart of the life sciences corridor of southwest Michigan at historic Brook Lodge, the original estate of The Upjohn Company founder.
  
  
• 2006-05-15 - MPI Research Invites You to Attend the 2nd Annual Optimizing Preclinical Outsourcing Conference - MPI Research would like to invite you to attend IIR's Second Annual Optimizing Preclinical Outsourcing Conference to be held in Cambridge, MA, June 26-28, 2006. Meeting attendees include such companies as Pfizer Global R&D, Allergan, Eli Lilly, and Chiron Corp. It promises to be a spectacular event. MPI Research is a proud sponsor of this conference.
  
  
• 2006-02-09 - Join MPI Research in Booth 501 at the 45th annual Society of Toxicology meeting March 5-9 in San Diego to celebrate our decade of excellence! - MPI Research in commemorationg its 10th year of bringing safer, healthier pharmaceutical and biotech products to the world, and would be honored to have you share in our celebration!
  
  

• 2006-01-06 - MPI Research Board of Directors Approves $50 Million for 2006 Expansion! ! - In 2005 MPI Research invested $25 million in our facility, creating 100,000 ft2 of added laboratory space.  In response to further increased demand for MPI Research services, the Board of Directors recently approved another $50 million for 300,000 ft2 of new construction to come online in 2006.
  
  
• 2005-09-14 - ICH Recommends S7B QT Prolongation Guidelines for Implementation. MPI CardIon Laboratories Stand Ready to Assist with Key Preclinical Assays! - In May of 2005 the International Conference on Harmonization (ICH) recommended for full adoption and implementation the long discussed and debated S7B guidelines for the preclinical evaluation of the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals.
  
  
• 2005-05-24 - MPI Research Expands Expertise and Support for Medical Device Research! - In a continuous effort to improve research support for the medical device industry, MPI Research is proud to announce several major advances to our surgical program.
  
  
• 2005-03-03 - MPI Research Announces the Realignment of Analytical and DMPK Services into its MPI Analytical Division at the Annual Society of Toxicology Meeting in New Orleans, LA! - MPI Research announced today the restructuring of its analytical, ADME and pharmacokinetic services under one umbrella, MPI Analytical. In an effort to more closely align related services, senior management made the decision to place DMPK and analytical services into one integrated cohesive management structure.
  
  
• 2005-02-22 - MPI Research Invites You to Attend Three Important Breakfast Seminars at the 44th Annual Meeting of the Society of Toxicology, March 7th, 8th, and 9th in New Orleans, LA! - MPI Research is proud to participate in the 44th annual meeting of the Society of Toxicology March 6-10, 2005 in New Orleans, LA. In recognition of the opportunity for continuing education that the SOT provides its members, we are pleased to provide three stimulating breakfast discussions during this year’s meeting. MPI Research is honored to have three leading experts in their fields offer valuable insight and expertise on topics that are critical issues in today’s efforts to bring safe and effective therapeutics and medical devices to the marketplace.
  
  
• 2005-01-21 - MPI Research Continues To Set New Standards for Reporting Preclinical Studies! - MPI Research has always set itself apart from other preclinical laboratories by offering sponsors fast starting, high quality, preclinical research at competitive prices.
  
  
• 2004-11-03 - MPI Research Invites 2004 American College of Toxicology Attendees to Hear Dr. Ted Baird Discuss the Use of Mini-Swine for Evaluation of Cardiovascular Safety of New Drugs - MPI Research is pleased to announce that Theodore Baird, Ph.D. will be speaking at the upcoming American College Of Toxicology meeting in Palm Springs, California. As a part of the Safety Pharmacology symposium on...
  
  
• 2004-10-29 - MPI Research Becomes First US Preclinical CRO to Add PET Molecular Imaging Services - MPI Research is proud to announce the availability of Positron Emission Tomography (PET) services through a collaborative effort with Luminare Molecular, a new, leading edge Molecular Imaging Company...
  

Home | News